{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:08:25Z","timestamp":1792782505697,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"University of Burgundy-Franche-Comt\u00e9","id":[{"id":"https:\/\/ror.org\/03k1bsr36","id-type":"ROR","asserted-by":"crossref"}]},{"name":"French National Research Agency","award":["Program \u201cInvestissements d\u2019Avenir\u201d with refe"],"award-info":[{"award-number":["Program \u201cInvestissements d\u2019Avenir\u201d with refe"]}],"id":[{"id":"https:\/\/ror.org\/00rbzpz17","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Institute of Health and Medical Research"},{"DOI":"10.13039\/501100014088","name":"AstraZeneca France","doi-asserted-by":"publisher","award":["grantsfrom AstraZeneca"],"award-info":[{"award-number":["grantsfrom AstraZeneca"]}],"id":[{"id":"10.13039\/501100014088","id-type":"DOI","asserted-by":"publisher"}]},{"name":"R\u00e9gion Bourgogne-Franche Comt\u00e9","award":["Fonds Europ\u00e9ens de D\u00e9veloppement R\u00e9gional"],"award-info":[{"award-number":["Fonds Europ\u00e9ens de D\u00e9veloppement R\u00e9gional"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s00125-026-06810-6","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T11:08:49Z","timestamp":1784286529000},"page":"3301-3311","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dapagliflozin does not impair LDL catabolism and induces a shift towards a closer to normal VLDL1\/VLDL2 catabolism in individuals with type 2 diabetes: a randomised in vivo kinetic study"],"prefix":"10.1007","volume":"69","author":[{"given":"Bruno","family":"Verg\u00e8s","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexia","family":"Rouland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Bouillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Paul","family":"Pais de Barros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coralie","family":"Fourmont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perrine","family":"Buffier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Jourdan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Vergas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Duvillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"issue":"1","key":"6810_CR1","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12933-018-0728-6","volume":"17","author":"TR Einarson","year":"2018","unstructured":"Einarson TR, Acs A, Ludwig C, Panton UH (2018) Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007\u20132017. Cardiovasc Diabetol 17(1):83. https:\/\/doi.org\/10.1186\/s12933-018-0728-6","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"6810_CR2","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.diabres.2013.07.009","volume":"102","author":"Y Wang","year":"2013","unstructured":"Wang Y, Lammi-Keefe CJ, Hou L, Hu G (2013) Impact of low-density lipoprotein cholesterol on cardiovascular outcomes in people with type 2 diabetes: a meta-analysis of prospective cohort studies. Diabetes Res Clin Pract 102(1):65\u201375. https:\/\/doi.org\/10.1016\/j.diabres.2013.07.009","journal-title":"Diabetes Res Clin Pract"},{"issue":"5","key":"6810_CR3","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1007\/s00125-015-3525-8","volume":"58","author":"B Verg\u00e8s","year":"2015","unstructured":"Verg\u00e8s B (2015) Pathophysiology of diabetic dyslipidaemia: where are we? Diabetologia 58(5):886\u201399. https:\/\/doi.org\/10.1007\/s00125-015-3525-8","journal-title":"Diabetologia"},{"issue":"22","key":"6810_CR4","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373(22):2117\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"issue":"7","key":"6810_CR5","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377(7):644\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1611925","journal-title":"N Engl J Med"},{"issue":"4","key":"6810_CR6","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380(4):347\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1812389","journal-title":"N Engl J Med"},{"issue":"9","key":"6810_CR7","doi-asserted-by":"publisher","first-page":"4502","DOI":"10.7150\/thno.54498","volume":"11","author":"Z Liu","year":"2021","unstructured":"Liu Z, Ma X, Ilyas I et al (2021) Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics. Theranostics 11(9):4502\u201315. https:\/\/doi.org\/10.7150\/thno.54498","journal-title":"Theranostics"},{"issue":"12","key":"6810_CR8","doi-asserted-by":"publisher","first-page":"10164","DOI":"10.3390\/ijms241210164","volume":"24","author":"F Piccirillo","year":"2023","unstructured":"Piccirillo F, Mastroberardino S, Nusca A et al (2023) Novel antidiabetic agents and their effects on lipid profile: a single shot for several cardiovascular targets. Int J Mol Sci 24(12):10164. https:\/\/doi.org\/10.3390\/ijms241210164","journal-title":"Int J Mol Sci"},{"issue":"2","key":"6810_CR9","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.jacl.2017.01.018","volume":"11","author":"HE Bays","year":"2017","unstructured":"Bays HE, Sartipy P, Xu J, Sj\u00f6str\u00f6m CD, Underberg JA (2017) Dapagliflozin in patients with type II diabetes mellitus, with and without elevated triglyceride and reduced high-density lipoprotein cholesterol levels. J Clin Lipidol 11(2):450-458.e1. https:\/\/doi.org\/10.1016\/j.jacl.2017.01.018","journal-title":"J Clin Lipidol"},{"issue":"3","key":"6810_CR10","doi-asserted-by":"publisher","first-page":"365","DOI":"10.2337\/dc14-0666","volume":"38","author":"S Matthaei","year":"2015","unstructured":"Matthaei S, Bowering K, Rohwedder K et al (2015) Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial. Diabetes Care 38(3):365\u201372. https:\/\/doi.org\/10.2337\/dc14-0666","journal-title":"Diabetes Care"},{"issue":"2","key":"6810_CR11","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.dsx.2019.01.016","volume":"13","author":"M Calapkulu","year":"2019","unstructured":"Calapkulu M, Cander S, Gul OO, Ersoy C (2019) Lipid profile in type 2 diabetic patients with new dapagliflozin treatment; actual clinical experience data of six months retrospective lipid profile from single center. Diabetes Metab Syndr Clin Res Rev 13(2):1031\u20134. https:\/\/doi.org\/10.1016\/j.dsx.2019.01.016","journal-title":"Diabetes Metab Syndr Clin Res Rev"},{"issue":"1","key":"6810_CR12","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12933-016-0491-5","volume":"16","author":"T Hayashi","year":"2017","unstructured":"Hayashi T, Fukui T, Nakanishi N et al (2017) Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin. Cardiovasc Diabetol 16(1):8. https:\/\/doi.org\/10.1186\/s12933-016-0491-5","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"6810_CR13","doi-asserted-by":"publisher","first-page":"605","DOI":"10.14740\/jocmr3046w","volume":"9","author":"H Yanai","year":"2017","unstructured":"Yanai H, Hakoshima M, Adachi H et al (2017) Effects of six kinds of sodium\u2013glucose cotransporter 2 inhibitors on metabolic parameters, and summarized effect and its correlations with baseline data. J Clin Med Res 9(7):605\u201312. https:\/\/doi.org\/10.14740\/jocmr3046w","journal-title":"J Clin Med Res"},{"issue":"6","key":"6810_CR14","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1111\/dom.13990","volume":"22","author":"KEC Bouter","year":"2020","unstructured":"Bouter KEC, van Bommel EJM, Jansen H et al (2020) The effect of dapagliflozin on apolipoprotein B and glucose fluxes in patients with type 2 diabetes and well-controlled plasma LDL cholesterol. Diabetes Obes Metab 22(6):988\u201396. https:\/\/doi.org\/10.1111\/dom.13990","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"6810_CR15","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12933-017-0529-3","volume":"16","author":"GP Fadini","year":"2017","unstructured":"Fadini GP, Bonora BM, Zatti G et al (2017) Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial. Cardiovasc Diabetol 16(1):42. https:\/\/doi.org\/10.1186\/s12933-017-0529-3","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"6810_CR16","doi-asserted-by":"publisher","first-page":"420","DOI":"10.2337\/dc14-1096","volume":"38","author":"I Tikkanen","year":"2015","unstructured":"Tikkanen I, Narko K, Zeller C et al (2015) Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care 38(3):420\u20138. https:\/\/doi.org\/10.2337\/dc14-1096","journal-title":"Diabetes Care"},{"issue":"10","key":"6810_CR17","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1111\/dom.12307","volume":"16","author":"A Liakos","year":"2014","unstructured":"Liakos A, Karagiannis T, Athanasiadou E et al (2014) Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 16(10):984\u201393. https:\/\/doi.org\/10.1111\/dom.12307","journal-title":"Diabetes Obes Metab"},{"key":"6810_CR18","doi-asserted-by":"publisher","first-page":"105068","DOI":"10.1016\/j.phrs.2020.105068","volume":"160","author":"A S\u00e1nchez-Garc\u00eda","year":"2020","unstructured":"S\u00e1nchez-Garc\u00eda A, Simental-Mend\u00eda M, Mill\u00e1n-Alan\u00eds JM, Simental-Mend\u00eda LE (2020) Effect of sodium-glucose co-transporter 2 inhibitors on lipid profile: a systematic review and meta-analysis of 48 randomized controlled trials. Pharmacol Res 160:105068. https:\/\/doi.org\/10.1016\/j.phrs.2020.105068","journal-title":"Pharmacol Res"},{"issue":"3","key":"6810_CR19","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/dom.12428","volume":"17","author":"B Bode","year":"2015","unstructured":"Bode B, Stenl\u00f6f K, Harris S et al (2015) Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55\u201380 years with type 2 diabetes. Diabetes Obes Metab 17(3):294\u2013303. https:\/\/doi.org\/10.1111\/dom.12428","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"6810_CR20","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.2337\/db16-0049","volume":"65","author":"F Briand","year":"2016","unstructured":"Briand F, Mayoux E, Brousseau E et al (2016) Empagliflozin, via switching metabolism toward lipid utilization, moderately increases LDL cholesterol levels through reduced LDL catabolism. Diabetes 65(7):2032\u20138. https:\/\/doi.org\/10.2337\/db16-0049","journal-title":"Diabetes"},{"issue":"9","key":"6810_CR21","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1161\/ATVBAHA.118.311339","volume":"38","author":"D Basu","year":"2018","unstructured":"Basu D, Huggins LA, Scerbo D et al (2018) Mechanism of increased LDL (low-density lipoprotein) and decreased triglycerides with SGLT2 (sodium\u2013glucose cotransporter 2) inhibition. Arterioscler Thromb Vasc Biol 38(9):2207\u201316. https:\/\/doi.org\/10.1161\/ATVBAHA.118.311339","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"11","key":"6810_CR22","doi-asserted-by":"publisher","first-page":"108625","DOI":"10.1016\/j.jdiacomp.2023.108625","volume":"37","author":"TH Shen","year":"2023","unstructured":"Shen TH, Farley JF (2023) Utilization and impact of SLGT2 inhibitors among diabetes patients in a nationally representative survey: findings from NHANES 2013\u20132020. J Diabetes Complications 37(11):108625. https:\/\/doi.org\/10.1016\/j.jdiacomp.2023.108625","journal-title":"J Diabetes Complications"},{"issue":"1","key":"6810_CR23","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s001250050004","volume":"43","author":"L Duvillard","year":"2000","unstructured":"Duvillard L, Pont F, Florentin E, Gambert P, Verg\u00e8s B (2000) Significant improvement of apolipoprotein B-containing lipoprotein metabolism by insulin treatment in patients with non-insulin-dependent diabetes mellitus. Diabetologia 43(1):27\u201335. https:\/\/doi.org\/10.1007\/s001250050004","journal-title":"Diabetologia"},{"issue":"8","key":"6810_CR24","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1007\/s00125-008-1046-4","volume":"51","author":"B Verg\u00e8s","year":"2008","unstructured":"Verg\u00e8s B, Florentin E, Baillot-Rudoni S et al (2008) Effects of 20 mg rosuvastatin on VLDL1-, VLDL2-, IDL- and LDL-ApoB kinetics in type 2 diabetes. Diabetologia 51(8):1382\u201390. https:\/\/doi.org\/10.1007\/s00125-008-1046-4","journal-title":"Diabetologia"},{"issue":"9","key":"6810_CR25","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.2337\/diab.39.9.1017","volume":"39","author":"MR Taskinen","year":"1990","unstructured":"Taskinen MR, Packard CJ, Shepherd J (1990) Effect of insulin therapy on metabolic fate of apolipoprotein B-containing lipoproteins in NIDDM. Diabetes 39(9):1017\u201327. https:\/\/doi.org\/10.2337\/diab.39.9.1017","journal-title":"Diabetes"},{"issue":"3","key":"6810_CR26","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1161\/01.ATV.0000155323.18856.a2","volume":"25","author":"JS Millar","year":"2005","unstructured":"Millar JS, Maugeais C, Ikewaki K et al (2005) Complete deficiency of the low-density lipoprotein receptor is associated with increased apolipoprotein B-100 production. Arterioscler Thromb Vasc Biol 25(3):560\u20135. https:\/\/doi.org\/10.1161\/01.ATV.0000155323.18856.a2","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"7","key":"6810_CR27","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/BF00280883","volume":"28","author":"DR Matthews","year":"1985","unstructured":"Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and \u03b2-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7):412\u2013419. https:\/\/doi.org\/10.1007\/BF00280883","journal-title":"Diabetologia"},{"issue":"11","key":"6810_CR28","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1093\/jn\/135.11.2499","volume":"135","author":"WG Bergen","year":"2005","unstructured":"Bergen WG, Mersmann HJ (2005) Comparative aspects of lipid metabolism: impact on contemporary research and use of animal models. J Nutr 135(11):2499\u2013502. https:\/\/doi.org\/10.1093\/jn\/135.11.2499","journal-title":"J Nutr"},{"issue":"10","key":"6810_CR29","doi-asserted-by":"publisher","first-page":"E63","DOI":"10.1161\/01.atv.20.10.e63","volume":"20","author":"J Pietzsch","year":"2000","unstructured":"Pietzsch J, Lattke P, Julius U (2000) Oxidation of apolipoprotein B-100 in circulating LDL is related to LDL residence time. In vivo insights from stable-isotope studies. Arterioscler Thromb Vasc Biol 20(10):E63\u2013E67. https:\/\/doi.org\/10.1161\/01.atv.20.10.e63","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"8","key":"6810_CR30","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1046\/j.1365-2362.2000.00755.x","volume":"30","author":"L Duvillard","year":"2000","unstructured":"Duvillard L, Pont F, Florentin E, Galland-Jos C, Gambert P, Verg\u00e8s B (2000) Metabolic abnormalities of apolipoprotein B-containing lipoproteins in non-insulin-dependent diabetes: a stable isotope kinetic study. Eur J Clin Invest 30(8):685\u2013694. https:\/\/doi.org\/10.1046\/j.1365-2362.2000.00755.x","journal-title":"Eur J Clin Invest"},{"issue":"10","key":"6810_CR31","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1161\/01.atv.0000032134.92180.41","volume":"22","author":"F Pont","year":"2002","unstructured":"Pont F, Duvillard L, Florentin E, Gambert P, Verg\u00e8s B (2002) Early kinetic abnormalities of apoB-containing lipoproteins in insulin-resistant women with abdominal obesity. Arterioscler Thromb Vasc Biol 22(10):1726\u201332. https:\/\/doi.org\/10.1161\/01.atv.0000032134.92180.41","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"6810_CR32","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1093\/ajcn\/78.1.47","volume":"78","author":"JMR Gill","year":"2003","unstructured":"Gill JMR, Brown JC, Caslake MJ et al (2003) Effects of dietary monounsaturated fatty acids on lipoprotein concentrations, compositions, and subfraction distributions and on VLDL apolipoprotein B kinetics: dose-dependent effects on LDL. Am J Clin Nutr 78(1):47\u201356. https:\/\/doi.org\/10.1093\/ajcn\/78.1.47","journal-title":"Am J Clin Nutr"},{"key":"6810_CR33","doi-asserted-by":"publisher","unstructured":"Gill JMR, Brown JC, Bedford D et al (2004) Hepatic production of VLDL1 but not VLDL2 is related to insulin resistance in normoglycaemic middle-aged subjects. Atherosclerosis 176(1):49\u201356. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2004.04.022","DOI":"10.1016\/j.atherosclerosis.2004.04.022"},{"issue":"5","key":"6810_CR34","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0026-0495(98)90239-6","volume":"47","author":"FB Kraemer","year":"1998","unstructured":"Kraemer FB, Takeda D, Natu V, Sztalryd C (1998) Insulin regulates lipoprotein lipase activity in rat adipose cells via wortmannin- and rapamycin-sensitive pathways. Metabolism 47(5):555\u20139. https:\/\/doi.org\/10.1016\/S0026-0495(98)90239-6","journal-title":"Metabolism"},{"issue":"15","key":"6810_CR35","doi-asserted-by":"publisher","first-page":"9030","DOI":"10.1016\/S0021-9258(18)81898-1","volume":"264","author":"CF Semenkovich","year":"1989","unstructured":"Semenkovich CF, Wims M, Noe L, Etienne J, Chan L (1989) Insulin regulation of lipoprotein lipase activity in 3T3-L1 adipocytes is mediated at posttranscriptional and posttranslational levels. J Biol Chem 264(15):9030\u20139038. https:\/\/doi.org\/10.1016\/S0021-9258(18)81898-1","journal-title":"J Biol Chem"},{"issue":"2","key":"6810_CR36","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1046\/j.1365-2362.2002.00945.x","volume":"32","author":"D Panarotto","year":"2002","unstructured":"Panarotto D, R\u00e9millard P, Bouffard L, Maheux P (2002) Insulin resistance affects the regulation of lipoprotein lipase in the postprandial period and in an adipose tissue-specific manner. Eur J Clin Invest 32(2):84\u201392. https:\/\/doi.org\/10.1046\/j.1365-2362.2002.00945.x","journal-title":"Eur J Clin Invest"},{"issue":"47","key":"6810_CR37","doi-asserted-by":"publisher","first-page":"23813","DOI":"10.1073\/pnas.1912573116","volume":"116","author":"J Miyamoto","year":"2019","unstructured":"Miyamoto J, Ohue-Kitano R, Mukouyama H et al (2019) Ketone body receptor GPR43 regulates lipid metabolism under ketogenic conditions. Proc Natl Acad Sci USA 116(47):23813\u201321. https:\/\/doi.org\/10.1073\/pnas.1912573116","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"6810_CR38","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.2337\/db15-1356","volume":"65","author":"E Ferrannini","year":"2016","unstructured":"Ferrannini E, Baldi S, Frascerra S et al (2016) Shift to fatty substrate utilization in response to sodium\u2013glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes 65(5):1190\u20135. https:\/\/doi.org\/10.2337\/db15-1356","journal-title":"Diabetes"},{"issue":"2","key":"6810_CR39","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.atherosclerosis.2004.12.038","volume":"180","author":"AM Palmer","year":"2005","unstructured":"Palmer AM, Nova E, Anil E et al (2005) Differential uptake of subfractions of triglyceride-rich lipoproteins by THP-1 macrophages. Atherosclerosis 180(2):233\u201344. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2004.12.038","journal-title":"Atherosclerosis"},{"issue":"4","key":"6810_CR40","doi-asserted-by":"publisher","first-page":"508","DOI":"10.2337\/dbi19-0007","volume":"69","author":"A Chait","year":"2020","unstructured":"Chait A, Ginsberg HN, Vaisar T, Heinecke JW, Goldberg IJ, Bornfeldt KE (2020) Remnants of the triglyceride-rich lipoproteins, diabetes, and cardiovascular disease. Diabetes 69(4):508\u201316. https:\/\/doi.org\/10.2337\/dbi19-0007","journal-title":"Diabetes"},{"issue":"9","key":"6810_CR41","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41569-022-00676-y","volume":"19","author":"J Bor\u00e9n","year":"2022","unstructured":"Bor\u00e9n J, Taskinen MR, Bj\u00f6rnson E, Packard CJ (2022) Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia. Nat Rev Cardiol 19(9):577\u201392. https:\/\/doi.org\/10.1038\/s41569-022-00676-y","journal-title":"Nat Rev Cardiol"},{"issue":"10","key":"6810_CR42","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.1111\/dom.15185","volume":"25","author":"DR Riley","year":"2023","unstructured":"Riley DR, Essa H, Austin P et al (2023) All-cause mortality and cardiovascular outcomes with sodium\u2013glucose co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and with combination therapy in people with type 2 diabetes. Diabetes Obes Metab 25(10):2897\u2013909. https:\/\/doi.org\/10.1111\/dom.15185","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"6810_CR43","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1210\/jc.2009-2480","volume":"95","author":"L Duvillard","year":"2010","unstructured":"Duvillard L, Dautin G, Florentin E, Petit JM, Gambert P, Verg\u00e8s B (2010) Changes in apolipoprotein B100-containing lipoprotein metabolism due to an estrogen plus progestin oral contraceptive: a stable isotope kinetic study. J Clin Endocrinol Metab 95(5):2140\u20136. https:\/\/doi.org\/10.1210\/jc.2009-2480","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"6810_CR44","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.atherosclerosis.2005.10.037","volume":"188","author":"AJ Tremblay","year":"2006","unstructured":"Tremblay AJ, Lamarche B, Ruel IL et al (2006) Effects of fenofibrate on apolipoprotein kinetics in patients with coexisting dysbetalipoproteinemia and heterozygous familial hypercholesterolemia. Atherosclerosis 188(1):203\u201312. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2005.10.037","journal-title":"Atherosclerosis"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-026-06810-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-026-06810-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-026-06810-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:39:19Z","timestamp":1790771959000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-026-06810-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":44,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["6810"],"URL":"https:\/\/doi.org\/10.1007\/s00125-026-06810-6","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"4 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"We are indebted to V. Grivet, C. Breuiller and I. Simoneau (all Clinical Research Unit of the Department of Endocrinology-Diabetology, CHU Dijon) for their help during the recruitment of individuals, to A. Cransac and V. Jost (both Department of Pharmacy, CHU Dijon) for the preparation of\n                      l-\n                      leucine 5,5,5 D\n                      3\n                      , to C. Gibassier and I. Rigaud (both Clinical Research Unit of the Department of Endocrinology-Diabetology, CHU Dijon) for dietary assistance, to M. Horbatiuk and I. Regazzoni (both Department of Biochemistry, CHU Dijon) for their invaluable technical assistance, and to S. Aho-Glele (Department of Epidemiology, CHU Dijon) for his help with statistical analysis.","order":1,"name":"Ethics","label":"Acknowledgements","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Anonymised data underlying the results and analysis can be made available to researchers upon reasonable request to the corresponding author after publication. A data access agreement needs to be signed in advance.","order":2,"name":"Ethics","label":"Data availability","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The authors acknowledge grants from AstraZeneca and from the French National Research Agency (ANR) under the programme \u2018Investissements d\u2019Avenir\u2019 with reference ANR-11-LABX-0021 (LipSTIC Labex). They also acknowledge financial support from the University of Burgundy-Franche-Comt\u00e9, the National Institute of Health and Medical Research (Inserm), the Region Burgundy \u2013 Franche Comt\u00e9, and the Fonds Europ\u00e9ens de D\u00e9veloppement R\u00e9gional. The study funders were not involved in the design of the study, the collection, analysis and interpretation of data, or writing the report, and did not impose any restrictions regarding the publication of the report.","order":3,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.","order":4,"name":"Ethics","label":"Authors relationships and activities","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"BV and LD designed the study. BV, BB, AR, CF, LD, PB TJ, JPPdB and VV contributed significantly to the acquisition of data. BV, LD and JPPdB were involved in the analysis and interpretation of data. BV wrote the first version of the manuscript, which was critically reviewed and finalised by all other authors. All authors approved the final version. BV is the guarantor of this work, and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.","order":5,"name":"Ethics","label":"Contribution statement","group":{"name":"EthicsHeading","label":"Ethics"}}]}}